## Abstract Urine samples collected from patients with colon carcinoma and from normal donors were tested for antigenic activity by the microcomplement fixation assay. When autologous serum was used as the antibody source, 65.4% (17/26) of the urine samples from patients with colon carcinoma were p
Determination of incidence and partial characterization of tumor-associated antigens found in the urine of patients bearing solid tumors
✍ Scribed by N. S. Rote; R. K. Gupta; D. L. Morton
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- French
- Weight
- 739 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Urine samples from patients with solid tumors and from donors without malignant disease were concentrated and tested for the presence of tumor‐associated antigens. In the complement‐fixation assay using serum from a source autologous with the source of the urine, 87.4% of cancer patients were positive, while only 6.9% of control donors were positive. When serum from an allogeneic source was used, 94.7% of cancer patients and 35.1% of control donors were positive. Absorption of a cancer patient's serum with autologous tumor cells removed antibody activity to autologous and allogeneic urine samples. Normal lymphocytes, skin, or muscle‐cell suspensions were ineffective as absorbants. The excretion of antigen into urine is dependent upon the presence of tumor. Surgical removal of tumor resulted in cessation of antigen excretion. The urine remained antigen‐negative as long as the patient remained disease‐free. The antigenic activity was heat‐stable and comprised molecules of > 1,000,000 daltons which could be dissociated into smaller molecular weight active fractions by treatment with 6 m urea.
📜 SIMILAR VOLUMES
## Abstract Using allogeneic antibody, we previously described a highmolecular‐weight glycoprotein in the urine of 68% of melanoma patients. This glycoprotein has been termed urinarytumor‐associated antigen (U‐TAA). A murine monoclonal antibody (MAb) specific for U‐TAA (AD1‐40F4) has been developed
BACKGROUND. The use of new prognostic factors as guidelines for the indication of treatment ancillary to surgery has been advocated for patients with nonsmall cell lung carcinoma (NSCLC). This article is an analysis of the prognostic information derived from determination of tumor-tissue cytosolic c
The urine of 68% of melanoma patients contains a high molecular weight glycoprotein which is expressed by melanoma cells and reacts with autologous antibody. Since high levels of this antigen in urine correlate with disease recurrence in surgically treated melanoma patients, it has been termed urina